Topics include pharmacogenomics implementation, population-scale genomic initiatives, and adoption of precision medicine.

CLS experts present economic, clinical, & humanistic outcomes of a comprehensive medication management program.

CLS’ CSO, Jeffrey A. Shaman participates in expert Dx testing to mitigate risk in COVID-19 panel

CLS’ President & CEO, Scott Megill, will explain the value of scalable precision medicine and the benefits of PGx.

Coriell Life Sciences participates in National Council on Teacher Retirement’s (NCTR) Driving for Success Virtual Conference 2020.  This conference represents the opportunity for all pension systems’ staff, members, and key stakeholders to come together, collaborate, and share ideas while hearing the latest pension news and challenges. “Now more than ever we need to stay connected!” […]

Precision public health focuses on populations and uses genetic testing to assess presumably healthy people without identified personal or family history of heritable disease or suboptimal response to drugs. The goals include early identification of health risks and modification of preventive care approaches, as well as safer and more effective medication use. Panelists Jeffrey A. […]

Join Coriell Life Sciences at APHA 2019, the annual meeting and expo of the American Public Health Association, where the company will present its latest precision public health findings at the Genomics Forum on November 5 at 10:30 a.m.  The APHA Annual Meeting, one of the nation’s most influential public health events, will be held November […]

Coriell Life Sciences was proud to accept the Excellence Award in the Cost Containment category at the Pharmacy Benefit Management Institute’s (PBMI) 25th Annual National Conference in Orlando, FL on March 3, 2020. “Pharmacogenomics has evolved over the last decade and is becoming more utilized in drug benefit programs. We are thrilled to present Coriell Life Sciences (CLS) with […]